Prognostic importance of nuclear DNA content measured by flow cytometry for patients with adenocarcinoma of the prostate.
In 1990, nuclear DNA ploidy analysis for prostate cancer is no longer a research investigation. It is now a routine economical clinical test. Ploidy analysis, carried out by either flow or static cytometry, provides unique prognostic information which is not replaceable by standard clinical variables such as tumor stage, histologic grade, or tumor volume. My colleagues and I at the Mayo Clinic routinely utilize ploidy information on radical prostatectomy specimens to guide in the selection of adjuvant therapy for patients treated by this type of surgery and to help gauge their prognosis. We believe that rational management of patients with all stages of prostate carcinoma now requires knowledge of each individual tumor's ploidy pattern.